SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Cantor Fitzgerald Reiterates Overweight on CymaBay Therapeutics, Raises Price Target to $15

Cantor Fitzgerald analyst Eliana Merle reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Overweight and raises the price target from $5 to $15.

Benzinga · 05/12/2020 11:28

Cantor Fitzgerald analyst Eliana Merle reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Overweight and raises the price target from $5 to $15.